GlassScriptPhysician profile
Minas S Constantinides
NPI 1194823096
$6,796.34
in general payments reported to CMS, 2019-2025
26 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 86% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $322 · 2021: $568 · 2022: $515 · 2023: $1,416 · 2024: $1,455 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,191.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,634.20 | 2023-2025 | Botox |
| Galderma Laboratories, L.P. | $1,185.37 | 2019-2025 | Dysport |
| Allergan, INC. | $837.73 | 2019-2022 | |
| Lilly USA, LLC | $306.30 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Inspire Medical Systems, INC. | $305.83 | 2022-2025 | Inspire |
| Incyte Corporation | $225.47 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $203.78 | 2023-2025 | Adbry |
| Ucb, INC. | $195.91 | 2023-2024 | Bimzelx, Cimzia |
| Medtronic, INC. | $158.91 | 2021 | |
| Acclarent, INC | $153.81 | 2023 | Acclarent Aera, Trudi Nav Cable |
| Revance Therapeutics, INC. | $146.68 | 2025 | Daxi, Daxxify |
| Novartis Pharmaceuticals Corporation | $138.43 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $138.39 | 2021 | |
| Olympus America INC. | $138.07 | 2019 | |
| Janssen Biotech, INC. | $136.43 | 2021-2025 | Tremfya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $122.10 | 2022 | |
| Glaxosmithkline, LLC. | $116.32 | 2024 | Nucala |
| Ethicon US, LLC | $115.55 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.47 | 2022-2025 | Cabtreo, Arazlo, Siliq |
| Genzyme Corporation | $104.05 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $92.47 | 2019-2025 | Winlevi, Absorica Ld |
| Biofrontera INC. | $72.08 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $68.46 | 2019 | |
| Aclaris Therapeutics, INC. | $38.40 | 2019 | |
| Journey Medical Corporation | $34.42 | 2019 | |
| Lnhc, INC | $20.71 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minas Constantinides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.